Molecular and Cellular Mechanisms of the Lysosomal Storage Disease Cystinosis

溶酶体贮积病胱氨酸中毒的分子和细胞机制

基本信息

  • 批准号:
    10434057
  • 负责人:
  • 金额:
    $ 72.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-09 至 2026-05-30
  • 项目状态:
    未结题

项目摘要

SUMMARY Lysosomal function is crucial for cell homeostasis, autophagy, nutrient sensing, apoptosis and tissue remodeling. In lysosomal storage disorders (LSDs), characterized by genetic defects leading to anomalous accumulation of metabolites in lysosomes, cells are affected by lysosomal malfunction frequently leading to cell death. Cystinosis is a lysosomal storage disorder resulting from defects in the cystine transporter cystinosin (CTNS). Increased levels of intra-lysosomal cystine lead to cell malfunction and progressive tissue deterioration, which is especially manifested in kidneys. As with most LSDs, this leads to a slow but irreversible deterioration, organ dysfunction and early death. Patients with nephropathic cystinosis develop proximal tubule cell dedifferentiation, Fanconi syndrome and progressive renal injury, which are not corrected by the current therapy, cysteamine. Thus, cell malfunction and tissue failure occur despite cystine depletion, suggesting that cystine accumulation is not the only cause of all the defects observed in cystinosis. We recently revealed a defective mechanism of chaperone- mediated autophagy (CMA) in cystinosis. Defective CMA is directly linked to human disease, including kidney pathologies and neurological disorders. CMA defects in cystinosis are caused by mislocalization and downregulation of the only lysosomal CMA receptor, LAMP2A. Defective CMA activity correlates with high susceptibility to cell death in cystinosis. Importantly, the defect was not rescued by cystine depleting therapies supporting that it is independent of lysosomal overload. Our data highlight that CMA impairment is an important contributor to the pathogenesis of cystinosis and underline the need for new treatments to complement cystine- depletion therapies. Our research plan aims to elucidate the molecular and cellular mechanisms leading to abnormal CMA activity in cystinosis. We also propose translational approaches that utilize small-molecule activators of CMA to improve cellular function in cystinosis. Our Specific Aims are: Aim 1: To elucidate the molecular basis of the regulation of LAMP2A function in cystinosis. To this end, we will study the interplay between the CTNS protein and the CMA receptor LAMP2A and elucidate the mechanisms that mediate LAMP2A trafficking and destabilization at the lysosomal membrane in cystinosis. Aim 2: To determine the molecular basis of the regulation of CMA activity in cystinosis. We will study the mechanisms mediated by CTNS to regulate CMA function and will test the hypothesis that the rescue of CMA activity improves the function of proximal tubule cells from cystinotic patients. Aim 3: To utilize small-molecule CMA activators, in vivo, to improve renal function in cystinotic mice. We will correct cellular and renal function in cystinotic mice using CMA activators, alone, or in combination with cysteamine. Our research is highly significant because it aims to elucidate molecular mechanisms associated with a devastating human pathology and will help develop new therapies for the treatment of cystinosis and other human diseases.
概括 溶酶体功能对于细胞稳态、自噬、营养感应、细胞凋亡和组织重塑至关重要。 溶酶体贮积症 (LSD),其特征是遗传缺陷导致异常积累 由于溶酶体中的代谢物,细胞受到溶酶体功能障碍的影响,经常导致细胞死亡。胱氨酸病 是一种由胱氨酸转运蛋白胱氨酸 (CTNS) 缺陷引起的溶酶体贮积症。增加 溶酶体内胱氨酸的水平会导致细胞功能障碍和进行性组织恶化,尤其是 表现在肾脏。与大多数 LSD 一样,这会导致缓慢但不可逆转的恶化、器官功能障碍 和早逝。肾病性胱氨酸沉着症患者出现近端小管细胞去分化,Fanconi 综合征和进行性肾损伤,目前的疗法半胱胺无法纠正这些症状。因此,细胞 尽管胱氨酸耗尽,但仍会发生功能障碍和组织衰竭,这表明胱氨酸积累并不是 胱氨酸病中观察到的所有缺陷的唯一原因。我们最近揭示了伴侣的一个有缺陷的机制—— 胱氨酸中毒介导的自噬(CMA)。 CMA 缺陷与人类疾病(包括肾脏疾病)直接相关 病理学和神经系统疾病。胱氨酸病的 CMA 缺陷是由错误定位和 唯一的溶酶体 CMA 受体 LAMP2A 的下调。 CMA 活性缺陷与高 胱氨酸病对细胞死亡的敏感性。重要的是,胱氨酸消耗疗法未能挽救该缺陷 支持其独立于溶酶体过载。我们的数据强调 CMA 损伤是一个重要因素 胱氨酸病的发病机制的贡献者,并强调需要新的治疗方法来补充胱氨酸 耗尽疗法。我们的研究计划旨在阐明导致的分子和细胞机制 胱氨酸病中 CMA 活性异常。我们还提出了利用小分子的转化方法 CMA 激活剂可改善胱氨酸中毒的细胞功能。我们的具体目标是: 目标 1:阐明 胱氨酸中毒中 LAMP2A 功能调节的分子基础。为此,我们将研究相互作用 CTNS 蛋白和 CMA 受体 LAMP2A 之间的关系,并阐明介导 LAMP2A 的机制 胱氨酸病中溶酶体膜的运输和不稳定。目标 2:确定分子基础 胱氨酸中毒中 CMA 活性的调节。我们将研究 CTNS 介导的调节机制 CMA 功能并将检验拯救 CMA 活性可改善近曲小管功能的假设 来自胱氨酸患者的细胞。目标 3:利用小分子 CMA 激活剂在体内改善肾功能 在胱氨酸小鼠中。我们将单独使用 CMA 激活剂或联合使用 CMA 激活剂来纠正胱氨酸病小鼠的细胞和肾功能。 与半胱胺组合。我们的研究非常重要,因为它旨在阐明分子 与破坏性人类病理学相关的机制,将有助于开发新的疗法 治疗胱氨酸病和其他人类疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANA MARIA CUERVO其他文献

ANA MARIA CUERVO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANA MARIA CUERVO', 18)}}的其他基金

Decreased Protein Degradation in Aging
衰老过程中蛋白质降解减少
  • 批准号:
    9905323
  • 财政年份:
    2018
  • 资助金额:
    $ 72.53万
  • 项目类别:
Decreased Protein Degradation in Aging
衰老过程中蛋白质降解减少
  • 批准号:
    10393546
  • 财政年份:
    2018
  • 资助金额:
    $ 72.53万
  • 项目类别:
Molecular and Cellular Mechanisms of the Lysosomal Storage Disease Cystinosis
溶酶体贮积病胱氨酸中毒的分子和细胞机制
  • 批准号:
    10683169
  • 财政年份:
    2017
  • 资助金额:
    $ 72.53万
  • 项目类别:
Project 3: Autophagy dysfunction and neuronal activity in FTD
项目 3:FTD 中的自噬功能障碍和神经元活动
  • 批准号:
    9292170
  • 财政年份:
    2016
  • 资助金额:
    $ 72.53万
  • 项目类别:
Understanding Alzheimer's Disease in the Context of the Aging Brain
在大脑老化的背景下了解阿尔茨海默病
  • 批准号:
    9856238
  • 财政年份:
    2016
  • 资助金额:
    $ 72.53万
  • 项目类别:
Project 3: Autophagy dysfunction and neuronal activity in FTD
项目 3:FTD 中的自噬功能障碍和神经元活动
  • 批准号:
    10011929
  • 财政年份:
    2016
  • 资助金额:
    $ 72.53万
  • 项目类别:
Functional Consequences of Impaired Autophagy in Aging
衰老过程中自噬受损的功能后果
  • 批准号:
    8792022
  • 财政年份:
    2014
  • 资助金额:
    $ 72.53万
  • 项目类别:
Control of vesicular trafficking in the hepatocyte.
控制肝细胞中的囊泡运输。
  • 批准号:
    8633455
  • 财政年份:
    2013
  • 资助金额:
    $ 72.53万
  • 项目类别:
Control of vesicular trafficking in the hepatocyte
肝细胞中囊泡运输的控制
  • 批准号:
    9888362
  • 财政年份:
    2013
  • 资助金额:
    $ 72.53万
  • 项目类别:
Control of vesicular trafficking in the hepatocyte.
控制肝细胞中的囊泡运输。
  • 批准号:
    8838778
  • 财政年份:
    2013
  • 资助金额:
    $ 72.53万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 72.53万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了